相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
James M. Cleary et al.
CANCER DISCOVERY (2021)
FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+advanced gastric/gastroesophageal junction adenocarcinoma (GC).
Daniel V. T. Catenacci et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors
R. Bahleda et al.
ANNALS OF ONCOLOGY (2020)
Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis
Qinfen Xie et al.
DISEASE MARKERS (2020)
Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Sarinya Kongpetch et al.
JCO GLOBAL ONCOLOGY (2020)
The tumour microenvironment and immune milieu of cholangiocarcinoma
Luca Fabris et al.
LIVER INTERNATIONAL (2019)
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway
Piao Li et al.
JOURNAL OF IMMUNOLOGY (2019)
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
Sangeetha Palakurthi et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Apinya Jusakul et al.
CANCER DISCOVERY (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma
Francesco Sabbatino et al.
CLINICAL CANCER RESEARCH (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Rondell P. Graham et al.
HUMAN PATHOLOGY (2014)
Anchored multiplex FOR for targeted next-generation sequencing
Zongli Zheng et al.
NATURE MEDICINE (2014)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
分享论文
